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OBJECTIVES This study was undertaken to test the hypothesis that transplant coronary vasculopathy (CV)
is associated with increased myocardial protein expression of both tissue factor (TF) and
integrin v3.
BACKGROUND The vitronectin receptor (integrin v3) and TF have recently been found to play a key role
in apoptotic cell death and vascular endothelial cell injury.
METHODS A total of 77 heart transplant recipients underwent simultaneous endomyocardial biopsy and
intravascular ultrasound (IVUS) at one year of transplant. Patients with pre-existing donor
coronary atherosclerosis (n  35) or with acute rejection (grade 1A, n  10) at the time of
the IVUS were excluded from the analysis. The remaining 32 patients constitute the cohort
of the present study. A computerized biopsy score was derived based on the duration and
severity of cellular rejection. Both TF and v3 expression in the heart biopsy specimens were
evaluated by immunoperoxidase histochemistry and Western blot analysis.
RESULTS Patients with CV (n  24) had increased expression of v3 (2.7-fold, p  0.003) and TF
(7.9-fold, p 0.04) compared with patients without evidence of vasculopathy (n  8). In the
absence of myocardial fibrosis, v3 expression correlated significantly with the cellular
rejection score (r  0.58, p  0.02).
CONCLUSIONS Transplant vasculopathy is associated with increased expression of both TF and v3. The
significant correlation of v3 with cellular rejection suggests an important role for this
integrin in serving as a mechanistic link between cellular rejection and vasculopathy. (J Am
Coll Cardiol 2002;39:804–10) © 2002 by the American College of Cardiology Foundation
Allograft vasculopathy is the leading cause of death one year
after heart transplantation. Following cardiac transplanta-
tion, release of cytokines may cause endothelial injury and
stimulate proliferation of vascular smooth muscle cells
(VSMCs), leading to graft atherosclerosis (1).
Integrins are a family of cell surface adhesion receptors
that mediate cell-cell and cell-extracellular matrix interac-
tions (2). Both the vitronectin receptor (integrin v3) and
tissue factor (TF), a major regulator of coagulation and
hemostasis, have recently been shown to play a key role in
apoptosis, vascular endothelial cell injury and the inflam-
matory process of the immune response (3–8). However,
the roles of v3 and TF in the transplant population have
not been explored. We tested the hypothesis that coronary
vasculopathy (CV) is associated with upregulation of v3
and TF.
MATERIALS AND METHODS
Patient population. A total of 77 heart transplant recipi-
ents underwent serial endomyocardial biopsies and had
serial coronary intravascular ultrasound (IVUS) at baseline
(1 0.01 months) and one year of transplant. Patients with
pre-existing donor coronary atherosclerosis (defined as cor-
onary maximal intimal thickness [CMIT] 0.3 mm at
baseline, n  35) or with acute cellular rejection (grade
1A, n  10) at the annual IVUS were excluded from the
analysis to eliminate any variation in results that could be
influenced by these variables. The remaining 32 patients
constitute the present study. Patients gave informed consent
and the protocol was approved by the Ethics Review
Committee of our Institution.
Endomyocardial biopsy. Serial endomyocardial biopsy
specimens were evaluated histologically for acute cellular
rejection (International Society Heart Lung Transplant
criteria), acute vascular rejection, confirmed by immunoflu-
orescence (9,10), acute ischemic injury (myocyte necrosis)
and fibrosis. A computerized biopsy score was derived based
on the duration (days) and severity of the cellular rejection
component during the first year of transplant as recently
described (11). The following measurements were derived:
biopsy score  cellular rejection-1 score  cellular
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rejection-2 score; cellular rejection-1 score  cellular rejec-
tion score 0 to 6 months of transplant; and cellular
rejection-2 score cellular rejection score 6 to 12 months of
transplant.
Intravascular ultrasound. Intravascular ultrasound was
performed in 68 coronary vessels in 32 patients (2.1  0.1
arteries/patient). Coronary intimal thickness was measured
at baseline (1.0  0.01 months) and one year (12.0  0.01
months) of transplant. Coronary sites with minimum and
maximum intimal thickness were identified. Paired analysis
of matched sites (10 sites/patient) at one year measured the
change in CMIT. Coronary vasculopathy was defined as an
increase in CMIT 0.3 mm at any site at one year. A
CMIT of 0.3 to 0.5 mm was considered mild and0.5 mm
as advanced vasculopathy. Intimal thickening of 0.3 mm
was considered pathological on the basis of reported values
of intimal thickness in the young adult population (12,13).
Immunohistochemistry staining. Five endomyocardial bi-
opsy specimens were obtained from each patient at the
biopsy. Four were analyzed for histopathology, and one
(snap frozen in liquid nitrogen and stored at 75°C) for
immunoblotting. Immunoperoxidase staining for v3 and
TF was performed using rabbit antihuman integrin 3
polyclonal antibody (Chemicon International Inc., Te-
mecula, California) and goat antihuman TF polyclonal
antibody (American Diagnostica Inc., Greenwich, Con-
necticut), respectively. The staining was described as nega-
tive, weakly positive and strongly positive.
Myocardial fibrosis was evaluated by Trichome Masson
staining, and intramyocardial blood vessels by Movat pen-
tachrome staining. The number of blood vessels per high
power field were quantified in a blinded fashion in a
representative subpopulation of 15 patients (CMIT0.3 mm,
n 5; CMIT 0.3 to 0.5 mm, n 5 and CMIT0.5 mm
with evidence of fibrosis, n  5). Five sections were examined
for each specimen.
Immunoblotting. Protein expression of v3 and TF was
determined by Western blot analysis. Immunoblotting was
performed as described previously (14). Briefly, cardiac
tissue (3 to 5 mg wet weight per biopsy specimen) was
homogenized in 230 l of lysis buffer (10 mM N-(2-
Abbreviations and Acronyms
CMIT  coronary maximal intimal thickness
CV  coronary vasculopathy
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
IVUS  intravascular ultrasound
TF  tissue factor
VSMC  vascular smooth muscle cell
Table 1. Baseline Characteristics
Patients
Without CV
Patients
With CV
n 8 24
Gender (male) 7 (87%) 21 (87%)
Recipient age (yrs) 52  1.7 53  1.5
Donor age (yrs) 26  1.8 25  1.7
Etiology
Ischemic cardiomyopathy 6 (75%) 15 (63%)
Dilated cardiomyopathy 2 (25%) 9 (37%)
LVAD 2 (25%) 5 (21%)
Ischemia time (min) 174  8 171  7
Immunosuppressant medications
AZA/CSA/prednisone 4 (50%) 10 (42%)
MMF/CSA/prednisone 3 (37%) 13 (54%)
MMF/FK/prednisone 1 (13%) 1 (4%)
AZA  azathioprin; CSA  cyclosporin; CV  coronary vasculopathy, defined as
change in coronary maximal intimal thickness 0.3 mm over one year; LVAD  left
ventricular assist device as a bridge to transplant; MMF  mycophenolate mofetil;
FK  tacrolimus.
Figure 1. v3 and tissue factor immunohistochemistry staining in relation to coronary vasculopathy. Positive staining (brown) of both v3 (E, arrow,
vascular endothelium) and tissue factor (F, myocardial interstitium) in a patient with coronary vasculopathy demonstrated on intravascular ultrasound (D)
compared with a patient without evidence of coronary vasculopathy (A, B, C). Bar  50 m.
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Hydroxyethyl)piperazine-N-2-ethanesulfonic acid, pH 
7.4, 2 mM ethylenediamine-tetraacetic acid, 0.1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate,
5 mM dithiothreitol, 10 g/ml aprotinin, 1 mM phenyl-
methyl sulfonyl fluoride and 10 g/ml leupeptin). The
samples were then centrifuged at 14,000 v (16,000 g) at 4°C.
Tissue homogenate or supernatant of the homogenate was
separated on 10% polyacrylamide gels by Tris-Glycine
SDS-PAGE (Invitrogen Inc., Carlsbad, California). Pro-
tein concentration was measured using the bicinchoninic
acid method (PIERCE, Inc., Rockford, Illinois). The
amount of protein loaded in each well was either 25 or
35 g. After transfer to polyvinylidene fluoride membranes
(0.2 m, Bio-Rad Laboratories, Hercules, California.), the
membranes were blocked in 3% milk in tris-buffered saline
containing 0.1% tween-20. After two 10-min washes in
this solution, the membranes were incubated overnight
with rabbit antihuman integrin 3 polyclonal antibody
(Chemicon International Inc.), goat antihuman TF poly-
clonal antibody (American Diagnostica Inc.) and anti–
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
monoclonal antibody (Chemicon International Inc.). Pro-
tein expression was normalized to GAPDH and was quan-
tified by arbitrary units using densitometric ratio. Immuno-
blotting results were correlated with the IVUS findings.
Statistical analysis. Data are expressed as mean  SEM.
Categorical variables were compared by chi-square test and
continuous variables by Student’s t test, and Pearson corre-
lation coefficients were calculated. Intramyocardial blood
vessel quantification analysis was evaluated using mixed
modeling for repeated measurements for the overall group
comparison, with Tukey’s adjustment for pairwise compar-
ison. All analyses were done using SAS software, version 6
(SAS Institute, Cary, North Carolina). Differences were
considered significant at p  0.05.
RESULTS
The baseline characteristics of patients with and without CV
were comparable (Table 1). Eight patients had no evidence of
vasculopathy (Fig. 1A) and 24 patients developed CV
(CMIT 0.3 mm, Fig. 1D) at one year of transplant.
Immunohistochemistry staining. Compared with patients
having no CV who showed negative staining for 3 integrin
(Fig. 1B) and TF (Fig. 1C), patients with CV demonstrated
strong positive staining of the 3 integrin in the vascular
endothelium of the intramyocardial blood vessels (Fig. 1E,
arrow). Tissue factor stained strongly positive in the inter-
stitium of the myocardium (Fig. 1F).
Immunoblotting. Both v3 (2.7-fold, p  0.003) and
TF (7.9-fold, p  0.04) protein expression were signifi-
cantly increased in patients with CV (Fig. 2). When
patients with CV were analyzed according to the severity of
change in CMIT (Fig. 3), there was a trend toward a
reduced v3 protein expression in patients with advanced
CV (CMIT 0.5 mm). These patients had higher inci-
dence of post-transplant ischemic injury/fibrosis (8/12 vs.
2/12, p 0.04) than patients with CMIT 0.31 to 0.50 mm.
There was no significant difference in TF expression be-
tween these groups of patients. In the absence of post-
transplant ischemia/fibrosis, v3 protein expression corre-
lated significantly with cellular rejection score mainly during
the first six months of transplant (r  0.58, p  0.02, Fig.
4). However, this correlation was absent in patients whose
post-transplant course was complicated by the development
of fibrosis. Interestingly, a significant negative correlation
was noted between v3 protein expression and change in
Figure 2. Western blot analysis showing evidence of increased expression
of v3 (A, 2.7-fold) and tissue factor (TF) (B, 7.9-fold) in the presence
of coronary vasculopathy (CV) (coronary maximal intimal thickness
[CMIT] 0.3 mm) compared with patients without CV (CMIT 0.3
mm). GAPDH  glyceraldehyde-3-phosphate dehydrogenase.
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CMIT in the presence of post-transplant ischemia/fibrosis
(r  0.60, p  0.01, Fig. 5).
Further subgroup analysis of patients with advanced CV
progression (CMIT 0.5 mm) revealed significant reduced
myocardial v3 protein expression in patients with post-
transplant ischemia/fibrosis (Fig. 6). Careful analysis of the
cellular rejection component reveals that patients with
post-transplant ischemia/fibrosis had a significant reduced
cellular rejection score in the latter half of the year (Fig. 7).
Quantifying the number of intramyocardial blood vessels
per high power field showed that patients with CMIT 0.3 to
0.5 mm had increased number of blood vessels (10.4  1.1)
than patients without vasculopathy (4.7  0.2, p  0.001)
or patients with advanced CV complicated by post-
transplant ischemic injury/fibrosis (5.5  0.3, p  0.001).
DISCUSSION
The major findings of the present study are that both v3
and TF are upregulated in the presence of vasculopathy.
Integrin v3 has been shown to play a significant role in
endothelial cell migration and is essential for growth factor
and cytokine-induced VSMC proliferation (15). The bind-
ing of v3 with its corresponding ligands, such as vitro-
nectin, von Willebrand factor, fibronectin and throm-
bospondin, promotes a process of adhesive interactions
between endothelial cells and matrix proteins (16). This
integrin-mediated cell attachment regulates cell survival and
proliferation and function in signal transduction processes
(17). The activated endothelial cells in turn express TF
(18,19), a major regulator of coagulation. The relation
between v3 and TF is depicted in Figure 8. v3 has
been shown to co-stimulate the release of tumor necrosis
factor-alpha in macrophages (3). Tumor necrosis factor-
alpha in turn induces TF expression (20,21). Tissue factor is
also known to induce smooth muscle cell migration (22),
and its activity has been demonstrated within the coronary
intima in rat cardiac allografts (23). It may be a stimulus for
fibrin deposition observed in the allograft vessels (24).
Figure 3. Myocardial v3 and tissue factor (TF) protein expression in relation to the severity of coronary vasculopathy (CV). Relative decrease of v3
expression is noted in the presence of advanced CV (0.5 mm). GAPDH  glyceraldehyde-3-phosphate dehydrogenase.
Figure 4. Correlation of myocardial v3 protein expression with cellular rejection score during the first six months of transplant in the absence of
post-transplant ischemic injury/fibrosis. GAPDH  glyceraldehyde-3-phosphate dehydrogenase.
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Figure 5. Correlation of myocardial v3 protein expression with severity of coronary vasculopathy in patients with post-transplant ischemia/fibrosis.
CMIT  coronary maximal intimal thickness; GAPDH  glyceraldehyde-3-phosphate dehydrogenase.
Figure 6. Myocardial v3 and tissue factor (TF) protein expression in patients with coronary vasculopathy in relation to the presence or absence of
post-transplant ischemic injury/fibrosis. A significant decrease of v3 expression is noted in patients with post-transplant ischemic injury/fibrosis.
GAPDH  glyceraldehyde-3-phosphate dehydrogenase.
Figure 7. Biopsy score in patients with coronary vasculopathy in relation to the presence or absence of post-transplant ischemic injury/fibrosis. Patients with
fibrosis have reduced cellular rejection score at one year (Y), mainly during 6 to 12 months of transplant (Y2). *p  0.05; Y, fibrosis versus no fibrosis. **p 
0.006; Y2, fibrosis versus no fibrosis. Y1  cellular rejection score during the first 6 months of transplant.
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Expression of TF by fibroblasts is a likely explanation for
our findings of increased TF in the interstitium of the
myocardium in the presence of allograft vasculopathy (18).
Our study was limited to endomyocardial biopsies, so only
small vessels were studied. That may explain why we did not
note expression of TF on endothelial cells. Another possible
explanation may be that vasculopathy in our patients was
not severe enough to induce endothelial expression of TF.
The association of cellular rejection and transplant CV
has been debated in the literature (25). It has been proposed
that transplant vasculopathy is caused by an immune-
mediated inflammatory reaction with release of cytokines,
growth factors and chemotactic agents resulting in prolifer-
ation of VSMCs (26). Our results demonstrate that v3
may play a key role in this process.
Another major finding of this study is that patients with
CV whose transplant course was complicated by ischemia/
fibrosis had decreased v3 expression compared with
patients lacking such a complication. The decreased expres-
sion of v3 in patients with fibrosis could be related to the
fact that these patients had a reduced cellular rejection score
indicating less inflammatory component. It has been re-
cently suggested that post-transplant ischemia is associated
with subsequent microvascular damage and microvascular
deposition of fibrin (27) linked to depletion of tissue
plasminogen activator (28) and upregulation of endothelial
intercellular adhesion molecule-1 (29), leading to vascu-
lopathy. Our study did not evaluate the expression of these
adhesion molecules in allograft vasculopathy.
In conclusion, our results indicate that both v3 and TF
are upregulated in the presence of allograft vasculopathy.
Therapeutic interventions targeted against v3 may be
helpful in aborting the process of vascular endothelial injury.
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